NASDAQ:PULM

Pulmatrix - PULM Stock Forecast, Price & News

$4.65

-0.05 (-1.06%)

(As of 08/17/2022 12:00 AM ET)

Add

Compare

Today's Range: $4.53
▼
$4.89
50-Day Range: $4.18
▼
$5.25
52-Week Range: $4.03
▼
$20.80

Volume: 64,273 shs
Average Volume: 50,915 shs
Market Capitalization: $15.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Pulmatrix MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 115.1% Upside
$10.00 Price Target
Short Interest: Healthy
0.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($6.04) to ($6.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

721st out of 1,122 stocks

Pharmaceutical Preparations Industry

363rd out of 551 stocks

3.5

Analyst's Opinion

Consensus Rating
Pulmatrix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Pulmatrix has a forecasted upside of 115.1% from its current price of $4.65.
Amount of Analyst Coverage
Pulmatrix has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.47% of the float of Pulmatrix has been sold short.
Short Interest Ratio / Days to Cover
Pulmatrix has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pulmatrix has recently increased by 36.52%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Pulmatrix does not currently pay a dividend.
Dividend Growth
Pulmatrix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PULM.

2.5

News and Social Media Coverage

News Sentiment
Pulmatrix has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Pulmatrix this week, compared to 1 article on an average week.
Search Interest
5 people have searched for PULM on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
2 people have added Pulmatrix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pulmatrix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.63% of the stock of Pulmatrix is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Pulmatrix are expected to decrease in the coming year, from ($6.04) to ($6.25) per share.
Price to Book Value per Share Ratio
Pulmatrix has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pulmatrix (NASDAQ:PULM) Stock

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Pulmatrix Stock Performance

Shares of PULM opened at $4.70 on Wednesday. Pulmatrix has a 12-month low of $4.03 and a 12-month high of $20.80. The company's 50-day moving average price is $4.63 and its 200 day moving average price is $5.64.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Pulmatrix in a report on Wednesday. They issued a "hold" rating on the stock.

Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

PULM Stock News Headlines

August 9, 2022 | finance.yahoo.com

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update - Yahoo Finance

August 9, 2022 | americanbankingnews.com

Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com

August 8, 2022 | finance.yahoo.com

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

August 1, 2022 | americanbankingnews.com

Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com

August 1, 2022 | americanbankingnews.com

StockNews.com Begins Coverage on Pulmatrix (NASDAQ:PULM)

July 25, 2022 | americanbankingnews.com

Pulmatrix (NASDAQ:PULM) Now Covered by Analysts at StockNews.com

July 22, 2022 | bizjournals.com

Form D Friday: Boston startups raising funds July 2022 - Boston Business Journal - The Business Journals

July 14, 2022 | streetinsider.com

Form 8-K Pulmatrix, Inc. For: Jul 12 - StreetInsider.com

July 13, 2022 | seekingalpha.com

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100 - Seeking Alpha

July 12, 2022 | finance.yahoo.com

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

June 9, 2022 | streetinsider.com

Apexigen (BCAC) Appoints William Duke as CFO - StreetInsider.com

May 14, 2022 | baystreet.ca

Pulmatrix Lower on Q1 Results - Baystreet.ca

May 13, 2022 | baystreet.ca

Pulmatrix Lower on Q1 Results

May 12, 2022 | finance.yahoo.com

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update - Yahoo Finance

May 12, 2022 | finance.yahoo.com

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022 | nasdaq.com

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq

April 11, 2022 | benzinga.com

Global Dry Powder Inhalation Market Developments and Products Report 2022: Focus on Nicotine, Cannabinoid - Benzinga

April 7, 2022 | businesswire.com

Global Dry Powder Inhalation Developments and Products Report 2022: Nicotine, Cannabinoids, Botanicals and Other Non-Medical Substances Delivery by Big Tobacco and Pharma - Market Overview 1994-2022 - ResearchAndMarkets.com - Business Wire

March 29, 2022 | finance.yahoo.com

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

March 21, 2022 | benzinga.com

Pulmatrix Reports Top-Line Data Evaluating PUR1800 In Patients With Stable Chronic Obstructive Pulmonary - Benzinga

March 21, 2022 | finance.yahoo.com

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD - Yahoo Finance

March 21, 2022 | finance.yahoo.com

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

March 17, 2022 | benzinga.com

Pulmatrix Regains Compliance With Nasdaq Listing Requirements - Benzinga - Benzinga

March 17, 2022 | finance.yahoo.com

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

March 3, 2022 | nasdaq.com

PULM Stock Alert: Is Pulmatrix Really Soaring More Than 1,800% Today? - Nasdaq

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

PULM Company Calendar

Last Earnings: 3/29/2022
Today: 8/17/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PULM
CUSIP: N/A
CIK: 1574235
Web: www.pulmatrix.com
Phone: (781) 357-2333
Fax: 707-525-9906
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +115.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,170,000.00
Net Margins: -542.41%
Pretax Margin: -542.41%
Return on Equity: -42.29%
Return on Assets: -33.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.19
Quick Ratio: 8.19

Sales & Book Value

Annual Sales: $5.17 million
Price / Sales: 3.05
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.35 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 3,387,000
Free Float: 3,298,000
Market Cap: $15.75 million
Optionable: Optionable
Beta: 1.07

Key Executives

Mr. Teofilo David Raad MBA (Age 52)
Pres, CEO & Director
Comp: $713.51k
Dr. Alexander M. Klibanov Ph.D. (Age 72)
Founder
Mr. Peter Ludlum CMA (Age 67)
MBA, Interim CFO and Principal Accounting & Financial Officer
Dr. Margaret M. Wasilewski M.D. (Age 65)
Chief Medical Officer
Mr. David J. Maki J.D. (Age 64)
Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PULM Stock - Frequently Asked Questions

Should I buy or sell Pulmatrix stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PULM shares.
View PULM analyst ratings or view top-rated stocks.
What is Pulmatrix's stock price forecast for 2022?: 1 brokerages have issued 12 month target prices for Pulmatrix's shares. Their PULM share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 115.1% from the stock's current price.
View analysts price targets for PULM or view top-rated stocks among Wall Street analysts.
How have PULM shares performed in 2022?: Pulmatrix's stock was trading at $8.76 on January 1st, 2022. Since then, PULM stock has decreased by 46.9% and is now trading at $4.65.
View the best growth stocks for 2022 here.
When is Pulmatrix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our PULM earnings forecast.
How were Pulmatrix's earnings last quarter?: Pulmatrix, Inc. (NASDAQ:PULM) announced its earnings results on Tuesday, March, 29th. The biotechnology company reported ($2.43) earnings per share for the quarter, missing the consensus estimate of ($1.60) by $0.83. Pulmatrix had a negative trailing twelve-month return on equity of 42.29% and a negative net margin of 542.41%.
When did Pulmatrix's stock split?: Pulmatrix shares reverse split on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Pulmatrix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).
What is Pulmatrix's stock symbol?: Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."
Who are Pulmatrix's major shareholders?: Pulmatrix's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.60%), Citadel Advisors LLC (0.90%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Pulmatrix?: Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pulmatrix's stock price today?: One share of PULM stock can currently be purchased for approximately $4.65.
How much money does Pulmatrix make?: Pulmatrix (NASDAQ:PULM) has a market capitalization of $15.75 million and generates $5.17 million in revenue each year.
How can I contact Pulmatrix?: Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The official website for the company is www.pulmatrix.com. The biotechnology company can be reached via phone at (781) 357-2333, via email at rclarke@pulmatrix.com, or via fax at 707-525-9906.

This page (NASDAQ:PULM) was last updated on 8/17/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Pulmatrix - PULM Stock Forecast, Price & News

Pulmatrix MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month